Ocugen, Inc. has announced the pricing of its underwritten offering of 15,000,000 shares of common stock at an offering price of $1.50 per share, resulting in gross proceeds of $22.5 million. The offering is expected to close on or about January 22, 2026. The net proceeds from the offering will be used for general corporate purposes, capital expenditures, working capital, and general and administrative expenses.
This offering represents a significant fundraising effort for Ocugen, as it seeks to advance its pioneering biotechnology initiatives in gene therapies for blindness diseases. The financing is being led by RTW Investments, with additional participation from new and existing investors.
The offering is being made pursuant to a shelf registration statement on Form S-3, which became effective on May 1, 2024. Oppenheimer & Co. is acting as the sole book-running manager for the offering.
Ocugen, Inc. is focused on addressing significant unmet medical needs for large patient populations through its gene-agnostic approach. The company's modifier gene therapies aim to address complex diseases that may be caused by imbalances in multiple gene networks. Ocugen has programs in development for inherited retinal diseases and blindness diseases affecting millions globally, including retinitis pigmentosa, Stargardt disease, and geographic atrophy.
This press release contains forward-looking statements, and it's important to note that the offering is subject to customary closing conditions. As a result of these announcements, the company's shares have moved 4.32% on the market, and are now trading at a price of $1.69. For the full picture, make sure to review Ocugen's 8-K report.
